Market News How it works Learn FAQ
| RCT 0.1382 81.60% | NU 11.97 -21.04% | TGL 0.2617 18.15% | EWZ 32.715 -23.19% | SRTM 0.3394 -21.12% | BBD 2.835 -30.34% | SHFS 0.0989 -25.30% | GCDT 0.1322 -24.93% | ITUB 7.368 -23.81% | NWGL 0.0817 -0.37% | CLRO 4.67 43.69% | XP 14.8623 -51.13% | AZTR 1.265 76.92% | RBNE 0.1664 -12.42% | PBR 21.535 -17.68% | SGRY 23.055 46.38% | SOXL 85.96 2.87% | TSLL 10.8899 11.58% | SPCX 147.535 0.03% | VALE 12.0045 -3.19% | SPRC 1.4499 33.02% | NVD 4.04 -3.58% | CRWV 54.96 1.34% | JBLU 2.2085 -15.87% | SOXS 51.01 -2.76% | INTC 87.29 0.38% | GPUS 0.1679 -0.59% | NVDA 215 1.92% | TSLA 394.1 5.88% | IREN 24.64 -1.06% | ABEV 2.7991 -15.18% | TQQQ 67.83 2.32% | RENT 2.9899 30.00% | NOK 8.46 3.93% | INTR 4.415 -38.60% | PBR-A 18.92 -19.59% | XTND 2.8083 58.66% | SQQQ 38.76 -2.32% | BITO 10.6402 -1.75% | LUCD 0.5437 32.29% | SPDN 8.495 -0.53% | VBIO 0.8098 -13.85% | SBS 4.765 -25.55% | XXII 0.0999 -49.47% | SID 0.9233 -21.75% | STNE 7.96 -30.66% | KORU 10.6 0.19% | WFF 0.0765 -4.38% | RWM 14.4501 -0.69% | TSLG 5.45 11.91%
IMImunon, Inc. logo

Imunon, Inc. (IMNN)

NASDAQ Capital Market · Currency in USD
$1.29 ▲ +0.05 (+4.45%)
As of Oct 26, 11:11 AM ET. Market open.

Summary

Previous Close
$1.24
Open
$1.25
Day's Range
$1.23 – $1.29
52 Week Range
$0.96 – $4.90
Volume
5,444
Avg. Volume
134,291
Market Cap
$7.24M
Beta (5Y Monthly)
2.01
PE Ratio (TTM)
--
EPS (TTM)
-$2.81
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$10.00

Profile: Imunon, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
20
CEO
Stacy R. Lindborg
Website
imunon.com

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.61
DateEst.Actual
Aug 11, 2026-$0.87-$0.54Beat
May 12, 2026-$1.22-$0.84Beat
Mar 31, 2026-$1.43-$1.29Beat
Nov 13, 2025-$1.20-$1.16Beat
Aug 5, 2025-$3.09-$1.87Beat
May 12, 2025-$4.56-$3.65Beat

Analyst view

Consensus price target
$10.00 ▲ +675.3%
Range $10.00 – $10.00
Rating: Buy
Buy 75% · Hold 25% · Sell 0%

Get free alerts on IMNN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.